Please try another search
Breaking News
For the nine months ended 28 February 2022, Daito Pharmaceutical Co.,Ltd. revenues decreased 11% to Y33.58B. Net income applicable to common stockholders increased 8% to Y3.98B. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income benefited from Selling, general and administrative expe decrease of 2% to Y3.47B (expense), Subsidy increase from Y155K to Y23.2M (income).
Period Ending: | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 |
---|---|---|---|---|
Total Revenue | 10552 | 11932 | 12178 | 10531 |
Gross Profit | 2105 | 2715 | 2475 | 2369 |
Operating Income | 815 | 1208 | 1082 | 1106 |
Net Income | 787 | 869 | 683 | 940 |
Period Ending: | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 |
---|---|---|---|---|
Total Assets | 77351 | 74990 | 71516 | 70552 |
Total Liabilities | 25307 | 22869 | 20185 | 19581 |
Total Equity | 52044 | 52121 | 51331 | 50971 |
Period Ending: | Feb 29, 2024 | Nov 30, 2023 | Aug 31, 2023 | May 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review